Literature DB >> 17613405

Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.

Mardi Gomberg-Maitland1, Dezheng Huo, Raymond L Benza, Vallerie V McLaughlin, Victor F Tapson, Robyn J Barst.   

Abstract

BACKGROUND: The 6-minute walk test (6MWT) is the current standard to assess exercise capacity in pulmonary arterial hypertension (PAH). We compared the Naughton-Balke treadmill test reported in exercise metabolic equivalents (METs) with the 6MWT to evaluate whether MET could be a useful tool to assess exercise capacity.
METHODS: Serial 6MWTs followed by Naughton-Balke treadmill tests were performed in 47 PAH patients initiating a change in PAH therapy at baseline (i.e., Time 0) and Weeks 6, 12, 24 and 48; New York Heart Association (NYHA) functional class (FC) was also assessed. Hemodynamics data were recorded at baseline and Weeks 12 and 48. Treadmill time was converted to MET. Generalized estimating equation models, receiver-operating characteristic curves and fixed-effect linear models were utilized to create a model comparing 6MWT to MET.
RESULTS: MET correlated with 6MWT (r = 0.62). Piecewise linear function described the relationship between 6MWT and MET. 6MWT and MET were both associated with FC (p < 0.001) with similar ability to discriminate FC. Changes in hemodynamics in response to a change in PAH therapy correlated with changes in both 6MWT and MET. In less sick patients (i.e., FC II), the changes in 6MWT were less pronounced than with MET.
CONCLUSIONS: MET appears to be a reliable measure of exercise capacity in PAH, and correlates with 6MWT. MET can be used in clinical assessment and is helpful in demonstrating improvements in exercise capacity in less sick patients.

Entities:  

Mesh:

Year:  2007        PMID: 17613405     DOI: 10.1016/j.healun.2007.04.013

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

1.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

2.  Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension.

Authors:  Leighton Chan; Lisa M K Chin; Michelle Kennedy; Joshua G Woolstenhulme; Steven D Nathan; Ali A Weinstein; Gerilynn Connors; Nargues A Weir; Bart Drinkard; James Lamberti; Randall E Keyser
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

3.  The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).

Authors:  Katharina Cima; James Twiss; Rudolf Speich; Stephen P McKenna; Ekkehard Grünig; Christian M Kähler; Nicola Ehlken; Ursula Treder; Sigrid R Crawford; Lars C Huber; Silvia Ulrich
Journal:  Health Qual Life Outcomes       Date:  2012-09-13       Impact factor: 3.186

4.  Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension.

Authors:  Benjamin H Freed; Mardi Gomberg-Maitland; Sonal Chandra; Victor Mor-Avi; Stuart Rich; Stephen L Archer; E Bruce Jamison; Roberto M Lang; Amit R Patel
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

5.  Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates.

Authors:  Xingxing S Cheng; Daniel J Watford; Hiroyuki Arashi; Margaret R Stedman; Glenn M Chertow; Jane C Tan; William F Fearon
Journal:  Cardiorenal Med       Date:  2021-05-25       Impact factor: 4.360

6.  A study on nonlinear estimation of submaximal effort tolerance based on the generalized MET concept and the 6MWT in pulmonary rehabilitation.

Authors:  Jan Szczegielniak; Krzysztof J Latawiec; Jacek Łuniewski; Rafał Stanisławski; Katarzyna Bogacz; Marcin Krajczy; Marek Rydel
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

7.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

Authors:  T Thenappan; S J Shah; S Rich; L Tian; S L Archer; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2009-12-23       Impact factor: 16.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.